CureVac Says Final Data From Phase 2B/3 Trial Of COVID-19 Vaccine Candidate, Demonstrates Protection In Age Group Of 18 - 60, Statistical Success Criteria For Primary Endpoint Met On Basis Of 228 Adjudicated Cases